| Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study CK Cullum, TP Do, M Ashina, L Bendtsen, SS Hugger, A Iljazi, ... The Journal of Headache and Pain 23 (1), 61, 2022 | 51 | 2022 |
| Neuromuscular electrical stimulation preserves leg lean mass in geriatric patients A Karlsen, CK Cullum, KL Norheim, FU Scheel, AH Zinglersen, ... Medicine and science in sports and exercise 52 (4), 773-784, 2020 | 24 | 2020 |
| Inflammation relates to resistance training–induced hypertrophy in elderly patients KL Norheim, CK Cullum, JL Andersen, M Kjaer, A Karlsen Medicine & Science in Sports & Exercise 49 (6), 1079-1085, 2017 | 24 | 2017 |
| The Registry for Migraine (REFORM) study: methodology, demographics, and baseline clinical characteristics WK Karlsson, H Ashina, CK Cullum, RH Christensen, HM Al-Khazali, ... The Journal of Headache and Pain 24 (1), 70, 2023 | 17 | 2023 |
| Real-world efficacy and tolerability of fremanezumab in adults with chronic migraine: a 3-month, single-center, prospective, observational study CK Cullum, BA Chaudhry, TP Do, FM Amin Frontiers in Neurology 14, 1226591, 2023 | 7 | 2023 |
| Extreme ecchymoses in a migraine patient using concomitant treatment with calcitonin gene-related peptide receptor antibodies and fish oil supplements: a case report CK Cullum, MK Olsen, HB Kocadag, M Ashina, FM Amin BMC neurology 21, 1-4, 2021 | 6 | 2021 |
| No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study AM Florescu, LV Lannov, S Younis, CK Cullum, BA Chaudhry, TP Do, ... Cephalalgia 44 (1), 03331024231222915, 2024 | 4 | 2024 |
| Average steps per day as marker of treatment response with anti-CGRP mAbs in adults with chronic migraine: a pilot study FT Jantzen, BA Chaudhry, S Younis, I Nørgaard, CK Cullum, TP Do, ... Scientific Reports 14 (1), 18068, 2024 | 1 | 2024 |
| Use of non-pharmacological therapies in individuals with migraine eligible for treatment with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP)-signaling … L Rundblad, CK Cullum, S Sacco, R Gil-Gouveia, D Uludüz, TP Do, ... Frontiers in Pain Research 3, 935183, 2022 | 1 | 2022 |
| Real-world efficacy and tolerability of monoclonal antibody therapy targeting CGRP in chronic migraine CK Cullum Københavns Universitet, 2024 | | 2024 |
| Average-steps per day as marker of treatment response in adults with chronic migraine: a cross-sectional study FT Jantzen, BA Chaudhry, I Norgaard, CK Cullum, TP Do, FM Amin CEPHALALGIA 43 (1 supp), 319-319, 2023 | | 2023 |
| Use of non-pharmacological therapies in individuals with migraine eligible for treatment with monoclonal antibodies targeting calcitonin gene-related peptide (CGRP)-signaling … R Gil-Gouveia, FM Amin, TP Do, L Rundblad, CK Cullum, S Sacco, ... | | 2022 |
| Extreme ecchymoses in a migraine patient using concomitant treatment with erenumab and fish oil supplements CK Cullum, M Olsen, H Kocadag, M Ashina, F Amin EUROPEAN JOURNAL OF NEUROLOGY 28, 225-225, 2021 | | 2021 |